Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 359

Related Citations for PubMed (Select 22566746)

1.

Mixed dyslipidemias in primary care patients in France.

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E.

Vasc Health Risk Manag. 2012;8:247-54. doi: 10.2147/VHRM.S27668. Epub 2012 Apr 19.

2.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
3.

Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.

Gitt AK, Jünger C, Smolka W, Bestehorn K.

Clin Res Cardiol. 2010 Nov;99(11):723-33. doi: 10.1007/s00392-010-0177-z. Epub 2010 Jun 3.

4.

Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.

Ferrières J, Bérard E, Crisan O, Bongard V.

Arch Cardiovasc Dis. 2010 May;103(5):302-9. doi: 10.1016/j.acvd.2010.04.003. Epub 2010 Jun 4.

5.

Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.

Ambegaonkar BM, Bash LD, Chirovsky DR, Jameson K, Grant S, Nocea G, Pettersson B, Sazonov V.

Eur J Intern Med. 2013 Oct;24(7):656-63. doi: 10.1016/j.ejim.2013.07.005. Epub 2013 Aug 13.

PMID:
23953848
6.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators.

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.

PMID:
21450578
7.

Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.

Liberopoulos E, Vlasserou F, Mitrogianni Z, Papageorgantas I, Elisaf M; DYSIS-GREECE Investigators.

Angiology. 2012 Apr;63(3):184-93. doi: 10.1177/0003319711410226. Epub 2011 Jun 15.

PMID:
21676964
8.

Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.

Jones PH, Nair R, Thakker KM.

J Am Heart Assoc. 2012 Dec;1(6):e001800. doi: 10.1161/JAHA.112.001800. Epub 2012 Dec 19.

9.

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).

Raal FJ, Blom DJ, Naidoo S, Bramlage P, Brudi P.

Cardiovasc J Afr. 2013 Sep;24(8):330-8. doi: 10.5830/CVJA-2013-071.

10.

Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS).

Horgan S, Crowley J, Feely J, McAdam B, Shanahan E, Vaughan C.

Ir J Med Sci. 2011 Jun;180(2):343-9. doi: 10.1007/s11845-011-0702-8. Epub 2011 Mar 13.

PMID:
21400212
11.

Pitavastatin: clinical effects from the LIVES Study.

Teramoto T.

Atheroscler Suppl. 2011 Nov;12(3):285-8. doi: 10.1016/S1567-5688(11)70888-1. Review.

PMID:
22152283
12.

Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.

O'Connor PJ, Gray RJ, Maciosek MV, Fillbrandt KM, DeFor TA, Alexander CM, Weiss TW, Teutsch SM.

Prev Chronic Dis. 2005 Jul;2(3):A05. Epub 2005 Jun 15.

13.

Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database.

Sazonov V, Beetsch J, Phatak H, Wentworth C, Evans M.

Atherosclerosis. 2010 Jan;208(1):210-6. doi: 10.1016/j.atherosclerosis.2009.07.021. Epub 2009 Sep 20.

PMID:
19766999
14.

Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS).

Drexel H, Chazelle F, Fauer C, Lautsch D, Gitt AK.

Wien Klin Wochenschr. 2011 Oct;123(19-20):611-7. doi: 10.1007/s00508-011-0057-1. Epub 2011 Sep 29.

PMID:
21947362
15.

Total lipid management and cardiovascular disease in the dyslipidemia international study.

Ferrières J, Amber V, Crisan O, Chazelle F, Jünger C, Wood D.

Cardiology. 2013;125(3):154-63. doi: 10.1159/000348859. Epub 2013 Jun 1.

PMID:
23736147
16.

Prevalence and types of persistent dyslipidemia in patients treated with statins.

Reiner Ž, Tedeschi-Reiner E.

Croat Med J. 2013 Aug;54(4):339-45.

17.

Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.

Rodrigues CJ, Ribeiro HF, Ribeiro AB, Zanella MT, Batista MC.

Metab Syndr Relat Disord. 2012 Jun;10(3):195-201. doi: 10.1089/met.2011.0133. Epub 2012 Feb 7.

PMID:
22313142
18.

Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients.

Sudano I, Hess L, Noll G, Arnet D.

Swiss Med Wkly. 2011 May 13;141:w13200. doi: 10.4414/smw.2011.13200.

19.

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.

Sharma RK, Singh VN, Reddy HK.

Vasc Health Risk Manag. 2009;5:793-9. Epub 2009 Sep 24. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk